Peptides Are Coming Back
Coming Up:
June 22, 2026 12:00 am
The peptide compounding landscape is shifting. Following the FDA’s 2023 decision to restrict widely used peptides under the Category 2 bulk drug substances classification, a formal review is now officially underway. The Pharmacy Compounding Advisory Committee (PCAC) is scheduled to meet July 23-24, 2026 to evaluate seven compounds, including BPC-157 and TB-500, for potential reclassification.
This is a fast-moving regulatory window. Join Lianne Snyder, PIC and Director of Operations at PharmaLabs, for a live session that gives your clinic the facts it needs to prepare for any reclassifications from this meeting.
Agenda:
- The 2023 FDA Category 2 decision: how we got here and what it means
- The regulatory roadmap: how reclassification actually works and what the real legal trigger is
- Realistic timeline: when restricted peptides may become legally available through 503A pharmacies
- What your clinic can order right now while reclassification plays out
- Sourcing and quality: how to protect your patients and your practice from gray-market risks
Who Should Attend: Prescribers, practice owners, and clinic staff currently offering or exploring peptide, wellness, or longevity therapies.
Can’t make it live? Register anyway. All registrants receive first access to the on-demand recording when it becomes available.
About the Presenter:
Lianne Snyder, Pharm.D., is the Pharmacist-in-Charge (PIC) and Director of Operations at PharmaLabs in St. Petersburg, FL. She joined the PharmaLabs team in February 2024, bringing extensive experience in compounding and pharmacy operations optimization.
Lianne holds 18 active pharmacist licenses and is certified in USP 797 Sterile and USP 795 Non-Sterile Compounding, Bio-Identical Hormone Replacement Therapy, and Clinical Pharmacogenomics. She is a member of the Functional Medicine Pharmacist Alliance (FMPHA) and earned her degree from the University of Pittsburgh School of Pharmacy.